Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-O trial of alpelisib + olaparib versus chemotherapy in platinum-resistant or refractory BRCA-wild-type high-grade ovarian cancer
NL-OMON52195Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alpelisib, olaparib, paclitaxel and doxorubicin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Novartis. Primary endpoints: Progression-free survival by BIRC per RECIST 1.1 and Supplemental progression-free survival analysis. Started Sep 2022; status: completed.
02
Drugs
alpelisibolaparibpaclitaxeldoxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON52195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52195.